Recently, two major awards in the domestic capital market—the "Listed Company Golden Bull Award" and the "China Listed Company Value Selection" list—were announced one after another. With outstanding performance and excellent value return capability, Baiyang Pharmaceutical's parent company Baiyang Medicine (301015.SZ) stood out among thousands of listed companies, winning the "2023 Golden Bull Most Investment Valuable" and "Top 50 Growth Enterprise Market Listed Companies by Value" awards, demonstrating the capital market's high recognition of the company in corporate management, value return, development potential, and other aspects.

　　As one of the most authoritative and credible awards in China's capital market, the "Listed Company Golden Bull Award" is one of the Golden Bull series selection events hosted by China Securities Journal under Xinhua News Agency. Since its establishment in 1999, it has become the gold standard for measuring the high-quality development of listed companies with strict standards and professional evaluation, known in the industry as the "Oscar" of the financial field. With excellent profitability and strong growth potential, Baiyang Medicine won the "2023 Golden Bull Most Investment Valuable Award."

　　At the same time, the "18th China Listed Company Value Selection" event, hosted by Securities Times under People's Daily, is also in full swing. The event aims to commend leading listed companies with excellent fundamentals, active social responsibility practices, and standardized corporate governance. It has become an authoritative selection to establish value investment benchmarks in the capital market. Baiyang Medicine won the "Top 50 Growth Enterprise Market Listed Companies by Value" award based on its comprehensive performance in management, financial results, innovation capability, market influence, and social responsibility.

　　As a pharmaceutical industrialization platform supporting original innovation, since Baiyang Medicine entered the capital market, it has grown steadily. Not only have its core products maintained growth vitality, and brand effects gradually released, but the company has also strategically acquired pharmaceutical industries, extending the industrial chain upstream to the production end, successfully building a dual-engine development model of "manufacturing" and "commercialization" side by side, injecting continuous momentum into the company's long-term development. Meanwhile, the company continuously strengthens innovation collaboration with its parent company, introducing multiple innovative pharmaceutical and medical device products into clinical application.

　　In the first half of 2024, Baiyang Medicine achieved revenue of 3.595 billion yuan and a net profit attributable to the parent company of 369 million yuan. The company's net profit compound annual growth rate over the past three years reached 34.01%, showing strong growth momentum. While maintaining stable annual growth in operating performance, Baiyang Medicine also attaches great importance to the capital market and investor returns, continuously distributing cash dividends since its listing, sharing corporate development dividends with investors through concrete actions, achieving dual enhancement of corporate value and capital market recognition.

　　In the future, Baiyang Medicine will continue to stimulate new pharmaceutical and health productivity through innovation, continuously improve operational quality and core competitiveness, promote the continuous enhancement of brand value in the capital market, and while achieving sustainable high-quality corporate development, create greater value and returns for shareholders and investors with even better performance.